This company is no longer active
Second Sight Medical Products Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
24.9%
Tasa de crecimiento de los beneficios
48.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.9% |
| Tasa de crecimiento de los ingresos | -53.9% |
| Rentabilidad financiera | -14.4% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Second Sight, Nano Precision complete merger, renaming as Vivani Medical
Aug 30Second Sight Medical sheds ~17% after reverse stock split
Aug 19Second Sight stock rises as shareholders approve merger, name change, reverse stock split
Jul 29Second Sight stock rises ~10% on $1.1M funding from NIH for artificial vision implant trial
Jul 18Revisiting Second Sight Medical Products: The EV Is Negative And Being Short No Longer Looks Appealing
Mar 22Second Sight Medical rises defying legal battle; regains NASDAQ compliance
Jun 04Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Second Sight Medical Products. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -9 | 6 | 3 |
| 31 Mar 22 | 0 | -8 | 5 | 3 |
| 31 Dec 21 | 0 | -9 | 6 | 3 |
| 30 Sep 21 | 0 | -9 | 7 | 3 |
| 30 Jun 21 | 0 | -8 | 6 | 2 |
| 31 Mar 21 | 0 | -9 | 6 | 2 |
| 31 Dec 20 | 0 | -15 | 7 | 7 |
| 30 Sep 20 | 0 | -21 | 9 | 11 |
| 30 Jun 20 | 1 | -27 | 11 | 15 |
| 31 Mar 20 | 2 | -33 | 13 | 18 |
| 31 Dec 19 | 3 | -34 | 15 | 16 |
| 30 Sep 19 | 5 | -35 | 17 | 15 |
| 30 Jun 19 | 6 | -36 | 19 | 14 |
| 31 Mar 19 | 7 | -35 | 20 | 14 |
| 31 Dec 18 | 7 | -35 | 22 | 15 |
| 30 Sep 18 | 8 | -34 | 22 | 14 |
| 30 Jun 18 | 8 | -32 | 22 | 13 |
| 31 Mar 18 | 8 | -31 | 22 | 12 |
| 31 Dec 17 | 8 | -29 | 21 | 11 |
| 30 Sep 17 | 6 | -31 | 20 | 10 |
| 30 Jun 17 | 5 | -33 | 20 | 10 |
| 31 Mar 17 | 4 | -35 | 20 | 9 |
| 31 Dec 16 | 4 | -33 | 19 | 8 |
| 30 Sep 16 | 6 | -28 | 19 | 7 |
| 30 Jun 16 | 7 | -24 | 18 | 6 |
| 31 Mar 16 | 8 | -21 | 18 | 6 |
| 31 Dec 15 | 9 | -20 | 17 | 7 |
| 30 Sep 15 | 8 | -28 | 16 | 7 |
Ingresos de calidad: EYES is currently unprofitable.
Margen de beneficios creciente: EYES is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: EYES is unprofitable, but has reduced losses over the past 5 years at a rate of 24.9% per year.
Acelerando crecimiento: Unable to compare EYES's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: EYES is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).
Rentabilidad financiera
Alta ROE: EYES has a negative Return on Equity (-14.39%), as it is currently unprofitable.